Protalix Biotherapeutics Inc (PLX)

Currency in USD
1.780
-0.050(-2.73%)
Closed·

PLX Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
0.03 / 0.07
Revenue / Forecast
17.67M / 17.79M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/0.035--/16.8M----Free Sign Up
09/20250.03/0.0717.67M/17.79M-57.14%-0.67%Free Sign Up
06/2025--/0.1115.66M/23.1M-100%-32.21%Free Sign Up
03/2025-0.05/0.0310.11M/21.6M-266.67%-53.19%Free Sign Up
12/20240.1/0.118.22M/20.21M0%-9.85%Free Sign Up
09/20240.03/0.0617.96M/16.26M-50%+10.46%Free Sign Up
06/2024-0.03/0.0213.47M/12.5M-250%+7.76%Free Sign Up
03/2024-0.06/-0.063.75M/3.75M0%0%Free Sign Up
12/2023-0.03/-0.0310.47M/10.47M0%0%Free Sign Up
09/2023-0.04/-0.0410.34M/10M0%+3.4%Free Sign Up

All numbers in USD

Protalix Biotherapeutics Inc Earnings Call Summary for Q3/2025

  • Protalix (PLX) reported Q3 2025 EPS of $0.03, missing forecasts by 57.14%, with revenue at $17.67M slightly below expectations; stock plunged 13.55% to $1.85 in premarket trading.
  • Despite quarterly disappointment, nine-month revenue grew 24% YoY to $43.6M, with net loss improving to $1.1M from $3.6M in 2024; cash position remains strong at $29.4M.
  • Company plans to initiate Phase II clinical trial for PRX-115 gout treatment before year-end, with top-line results expected in Q3 2027.
  • CEO Dror Bashan positioned PRX-115 as a potential 'best-in-class therapy,' while CFO Gilad Memlock confirmed sufficient cash runway for at least 12 months to fund the upcoming trial.
Last Updated: 13/11/2025, 14:56
Read Full Transcript

FAQ

What Is Protalix's Earnings Per Share (TTM)?

The Protalix EPS (TTM) is 0.07.

When Is The Next Protalix Earnings Date?

Protalix will release its next earnings report on 11 Mar 2026.

What Is Protalix’s Revenue Forecasts For Upcoming Quarters?

Protalix’s revenue forecast is 16.80M.

How Did Protalix React to the Company's Latest Earnings Report?

Protalix reported a -57.14%% EPS surprise and a -0.67%% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -13.080%%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.